☆ 4.6 Editorial Material

Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials

EYE (2022)

Get Full Text
Add to Collection

Journal

EYE
Volume 36, Issue 4, Pages 679-680

Publisher

SPRINGERNATURE
DOI: 10.1038/s41433-021-01831-4

Keywords

-

Categories

Ophthalmology

Funding

  1. Research to Prevent Blindness

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.